C H Mallinckrodt
Overview
Explore the profile of C H Mallinckrodt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dickson S, Solomon A, Kivipelto M, Hartmann T, van Hees A, Brownlee A, et al.
J Prev Alzheimers Dis
. 2024 Jul;
11(4):992-997.
PMID: 39044510
Assessment of meaningfulness in randomized clinical trials (RCTs) in Alzheimer's disease (AD) is challenging, particularly in early disease. Converting clinical outcomes to disease progression time allows assessment of treatment effects...
2.
Dickson S, Haaland B, Mallinckrodt C, Dubois B, OKeefe P, Morgan M, et al.
J Prev Alzheimers Dis
. 2024 May;
11(3):529-536.
PMID: 38706269
Background: Disease modifying therapies (DMTs) may be most beneficial in early disease, when progression is slow and changes small, with clinical relevance difficult to interpret. Objectives: Time component tests (TCTs)...
3.
Mallinckrodt C, Bell J, Liu G, Ratitch B, OKelly M, Lipkovich I, et al.
Ther Innov Regul Sci
. 2020 Feb;
54(2):353-364.
PMID: 32072593
The draft ICH E9(R1) addendum stipulates that an estimator should align with its associated estimand and yield an estimate that facilitates reliable interpretations. The addendum further stipulates that assumptions should...
4.
Shafford H, Mallinckrodt C, Turner A, Hellyer P
Vet Anaesth Analg
. 2017 Apr;
28(2):103-104.
PMID: 28404330
No abstract available.
5.
Mallinckrodt C, Lin Q, Molenberghs M
Pharm Stat
. 2012 Nov;
12(1):1-6.
PMID: 23193075
The objective of this research was to demonstrate a framework for drawing inference from sensitivity analyses of incomplete longitudinal clinical trial data via a re-analysis of data from a confirmatory...
6.
Mallinckrodt C, Lin Q, Lipkovich I, Molenberghs G
Pharm Stat
. 2012 Sep;
11(6):456-61.
PMID: 22962024
An important evolution in the missing data arena has been the recognition of need for clarity in objectives. The objectives of primary focus in clinical trials can often be categorized...
7.
Mallinckrodt C, Prucka W
Clin Pharmacol Ther
. 2010 Oct;
88(5):592-4.
PMID: 20959845
In this issue, Merlo-Pich et al. present an enrichment-window approach that identifies sites with aberrant mean placebo responses and excludes data from those sites so as to improve drug-placebo discrimination...
8.
Prakash A, Risser R, Mallinckrodt C
Int J Clin Pract
. 2008 Jun;
62(8):1147-58.
PMID: 18564199
Aims: Various analytical strategies for addressing missing data in clinical trials are utilised in reporting study results. The most commonly used analytical methods include the last observation carried forward (LOCF),...
9.
Shelton R, Prakash A, Mallinckrodt C, Wohlreich M, Raskin J, Robinson M, et al.
Int J Clin Pract
. 2007 Jul;
61(8):1337-48.
PMID: 17627710
Aims: This was a post hoc analysis to determine whether baseline severity of depression influenced the efficacy of duloxetine in treating major depressive disorder (MDD) and to better characterise the...
10.
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
Perahia D, Wang F, Mallinckrodt C, Walker D, Detke M
Eur Psychiatry
. 2006 May;
21(6):367-78.
PMID: 16697153
Objective: Duloxetine doses of 80 and 120 mg/day were assessed for efficacy and safety in the treatment of major depressive disorder (MDD). Methods: In this randomized, double-blind trial, patients age...